In this thesis, we will utilize embryonic zebrafish tumour models to understand the interaction between engrafted human cancer cells and macrophages from the host, test drug administration modalities and anti-cancer efficacies of newly-developed PDT and PACT compounds, and test a light-triggered liposomal…

Promotor: E. Bouwman, Co-promotor: S. Bonnet

Promotores: J. Jonkers, K.E. de Visser

O-Nitrobenzyl groepen worden veel gebruikt als moleculaire beschermgroepen die je met licht kunt verwijderen.

Drug-target binding kinetics determine the time course of the central event in pharmacotherapy: Drug-target interaction.

How are new drugs developed? This question is central to the Minor Modern Drug Discovery (MDD), which covers the entire trajectory from disease to drug molecule and vice versa. The various research groups involved offer a complementary and interdisciplinary perspective by connecting the diverse subjects…

In previous studies at our laboratory it was demonstrated that drug exposure of HepG2 cells can lead to an altered TNFα-induced NF-κB oscillatory phenotype, concurrent with a synergistically increased sensitivity for TNFα-induced apoptosis.

Promotor: M. Danhof Co-promotor: O.E. Della Pasqua

Promotor: Prof.dr. R. Verpoorte, Co-Promotor: Dr. Young Hae Choi

In het onderzoeksprogramma Drug Discovery & Safety zijn we geïnteresseerd in de werkzaamheid en veiligheid van nieuwe medicijnen en nieuwe manieren om deze aspecten te bepalen. Daarvoor combineren we geavanceerde imaging en high-throughput screening technieken met computationele aanpakken zoals chem-…

This minor is focused on fundamental scientific research required for discovery of new drug targets and development of new drugs. Students learn how disease and drug-induced alterations in signaling pathways can be used for the discovery of new drug targets and the development of personalized drugs.

Hospital pharmacies face significant challenges: the demand for sterile drug reconstitutions is increasing, while specialized personnel remain scarce. Automation offers a potential solution, but its practical implementation in hospitals is still unclear.

A novel mathematical model describes spatial-temporal drug distribution within one or more brain units, which are cubic representations of a piece of brain tissue with brain capillaries at the edges.

Promotor: B.van de Water, Co-promotor: L.S.Price

Glucocorticoids are potent anti-inflammatory drugs widely used clinically to treat various inflammatory and immune conditions. However, two main clinical problems limit their use. GCs trigger severe side effects and they induce acquired glucocorticoid resistance, especially during chronic systemic treatment…

In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.

As leading cause of death worldwide, cancer is responsible for nearly 10 million deaths in 2020 according to World Health Organization (WHO). Cisplatin and its derivatives are commonly used chemotherapy agents for current cancer treatment in the clinics.

Over several decades, a variety of computational methods for drug discovery have been proposed and applied in practice. With the accumulation of data and the development of machine learning methods, computational drug design methods have gradually shifted to a new paradigm, i.e. deep learning methods…

This thesis aims to test in vitro pipelines to rapidly and cost-effectively identify molecular mechanisms that drive adverse outcomes in clinical use.

Promotor: Prof.dr. M. Danhof, Co-Promotor: J. de Jongh

Hoe kan de methode LEGO® Serious Play® bijdragen aan betere interdisciplinaire samenwerking en het ontwikkelen van gezamenlijke onderzoeksvoorstellen?

During the course of drug discovery translational steps are made.

Heart failure is a major health care problem with high mortality.

This thesis investigates how non-genetic factors, such as inflammation and concomitant medication, impact hepatic drug metabolism and subsequent drug metabolizing phenotype predictions.

This thesis describes the importance of being able to control the selectivity of potential drug candidates.

This thesis focuses on the application of lipid-based nanomedicine in drug delivery, including small molecular antitumor drugs and biomacromolecules including mRNA, and evaluates their biological performance.

Promotor: A. Kros

Actinobacteria are well known for the production of bioactive natural products, many of which have applications in the fields of human, animal and plant health. Subject of this thesis are the anthracyclines, glycosylated aromatic polyketides with potent anticancer activity.

Een pilletje op een festival, een biertje in de kroeg, of een sigaret bij de koffie. We wéten dat het slecht voor ons is, maar doen het toch. Hoe komt dat?

Clinical development of drugs for central nervous system (CNS) disorders has been particularly challenging and still suffers from high attrition rates.

Promotor: A.P. IJzerman Co-promotor: L.H. Heitman

Promotores: H.S. Overkleeft, G.A. van der Marel, Co-Promotor: R.G. Boot

Promotores: Prof.dr. P.C.W. Hogendoorn & Prof.dr. H.P. Spaink Co-promotor: Dr. B.E. Snaar-Jagalska

The aim of this thesis is to expedite and ensure the systematic accuracy of clearance scaling from adults to paediatric patients, with a special focus on drugs undergoing hepatic metabolism.

Discovery and development of Central Nervous System (CNS) drugs is hampered by high attrition rates.

Promotor: A.P.IJzerman, Co-Promotor: L.H. Heitman

This thesis aims to develop model-based approaches to optimize drug dosing in patients with overweight and (morbid) obesity.

Promotor: A.P.IJzerman Co-promotor: A. Bender

Promotor: B. van de Water

This thesis tackles the urgent challenge of antimicrobial resistance (AMR) through the design of novel antibacterial agents.

Universitair docent Jasper van der Steen vertelt bij radioprogramma Dit is de Dag meer over de geschiedenis van het koningshuis.

Growth hormone profiles are pulsatile and highly variable between individuals, limiting the implementation of mathemathical models to quantify an individual's secretion.

Promotores: C.A.J. Knibbe; J.N. van den Anker, Co-promotores: H.P.A. van Dongen; B. van Ramshorst